Search hospitals > California > Santa Barbara
Ridley-Tree Cancer Center
Claim this profileSanta Barbara, California 93105
Global Leader in Breast Cancer
Conducts research for Ovarian Cancer
Conducts research for Pancreatic Cancer
Conducts research for Lung Cancer
Conducts research for Cancer
33 reported clinical trials
9 medical researchers
Summary
Ridley-Tree Cancer Center is a medical facility located in Santa Barbara, California. This center is recognized for care of Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Lung Cancer, Cancer and other specialties. Ridley-Tree Cancer Center is involved with conducting 33 clinical trials across 65 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Kristie A. Bobolis, and Jorge A. Garcia-Young.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
2Ovarian Cancer
Stage III
Stage IV
BRCA1 positive
Top PIs
Ari Baron, MDAlta Bates Summit Medical Center-Herrick Campus8 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
30 reported clinical trials
68 drugs studied
Christopher JonesSutter Medical Center Sacramento4 years of reported clinical research
Studies Brain Tumor
Studies Prostate Cancer
26 reported clinical trials
69 drugs studied
Kristie A. BobolisSutter Medical Center Sacramento2 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
9 reported clinical trials
24 drugs studied
Jorge A. Garcia-YoungSutter Solano Medical Center/Cancer Center10 years of reported clinical research
Studies Melanoma
Studies Cutaneous Melanoma
7 reported clinical trials
20 drugs studied
Clinical Trials running at Ridley-Tree Cancer Center
Ovarian Cancer
Breast Cancer
Pancreatic Cancer
Esophageal cancer
Prostate Cancer
Kidney Cancer
Cancer
Breast cancer
Esophageal Adenocarcinoma
Gastric cancer
Olaparib +/- Bevacizumab
for Ovarian Cancer
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Recruiting2 awards Phase 34 criteria
Carboplatin + Mirvetuximab Soravtansine
for Ovarian Cancer
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC). Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States. Participants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years . There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Recruiting1 award Phase 24 criteria
ZN-c3
for Serous Carcinoma
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
Recruiting1 award Phase 21 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Ridley-Tree Cancer Center?
Ridley-Tree Cancer Center is a medical facility located in Santa Barbara, California. This center is recognized for care of Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Lung Cancer, Cancer and other specialties. Ridley-Tree Cancer Center is involved with conducting 33 clinical trials across 65 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Kristie A. Bobolis, and Jorge A. Garcia-Young.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.